U.S. Markets closed

Alnylam Pharmaceuticals, Inc. (ALNY)


NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
65.80-3.70 (-5.32%)
At close: 4:00PM EDT
People also watch
BMRNACORSGENACADALXN
  • Overall I think we will see upside for ALNY in the short-term. Perhaps a pullback next day or so could occur I suppose but are yall also seeing a further leg higher? google awesomeSTO-CKS - they offer pretty good trade alerrts. you dont have to trade their tickers but it definetly helps you recognize possible patterns for stocks you're trading.
  • Why raise before Patisiran results?
  • stock continues to sell off today as the biotech sector pulls back?
  • Why is this thing crashing
  • dilution is killing the stock today
    glad that i cashed in profit 2 days ago
    watching for re-entry point at much cheaper price
  • alny pulls out of health care conference last minute, in order raises $350million dilutive stock offering instead.
  • This one is going to $90 before September. Just added more to my position. Looking great technically as well..
  • Hey guys. Wondering what's today happening?
    Holding 1k shares.
  • See why biotech/pharma shareholders are adding this breakthrough wound care to their portfolio.

    • BioLargo’s 10Q states their Advanced Wound Care products are ready, all studies successfully completed, and they expect to file a 510K with FDA in less than 90 days
    • Woundcare market is over $6 Billion with high growth rate
    • Tanya Rhodes, ex VP of Smith & Nephew Wound Care Product Development is leading the BLGO/Clyra Medical 510K filing
    • BLGO/Clyra Medical Wound Care Products promote healing substantially better than competing products, fight infection better than competing products, are effective against resistant microbials, and are low cost
    • Sales could commence in first half of 2018
    • Sales and or licensing agreement/s could be very significant
    • Company is now commercializing several other disruptive products in large markets

    http://www.clyramedical.com

    https://www.sec.gov/Archives/edgar/data/880242/000143774917009469/blgo20170331_10q.htm

    Clyra Medical | Make Life Better
    www.clyramedical.com
  • (AXSM) Market Cap $92 M/Cash $55 M / 5x BIG Phase 3 programs in various indications targeting large Markets with first results in Q3 2017 =20 BAGGER ..FANTASTIC OPPORTUNITY !

    Undiscovered and massive undervalued Biotech Stock with lots of Big News on the way.This Stock is brutally undervalued with a Market cap of just $92 million and $55 million in cash .Founder and Ceo is the larget shareholder holding over 7 million shares (30%) more than 50% of O/S is owned by Insider and Institutions which is a great sign .

    This undiscovered stock could be the next 10 bagger gem if just one of their 5 ongoing Phase 3 programs is successful .GL

    Axsome (AXSM)

    Market-Cap: $92 Million
    Cash: $55 Million(cash runway into the first quarter of 2019.)
    Price:$4.10

    Shares Out: 23.5 Million

    Anticipated Near-Term Clinical Milestones

    Clinical Trial Initiations: -- Phase 2/3 clinical trial of AXS-05 in AD agitation (2Q 2017)

    Clinical Trial Readouts:

    -- Phase 3 COAST-1 trial of AXS-02 in knee OA associated with BMLs, interim analysis (3Q 2017)

    -- Phase 3 CREATE-1 trial of AXS-02 in CRPS, interim efficacy analysis (4Q 2017)

    -- Phase 3 STRIDE-1 trial of AXS-05 in TRD, top-line data (1Q 2018)

    New Presentation May
    http://phx.corporate-ir.net/External.File?item=UGFyZW50SUQ9NjcwNTc4fENoaWxkSUQ9Mzc3ODc0fFR5cGU9MQ==&t=1

    HUGE Pipeline targeting Billion Dollar Markets:
    http://axsome.com/wp-content/uploads/2016/11/Axsome_Dec2016_Pipeline.png

    AXS-05 Treatment Resistant Depression in Phase 3......Only 1 approved drug for TRD = unmet medical need. 3M patients in the U.S.

    AXS-05 Agitation in Alzheimer’s Disease in Phase 2/3.......No approved medication = unmet medical need. 2M patients in the U.S.

    AXS-02 Complex Regional Pain Syndrome (CRPS) in Phase 3 (Orphan+Fast Track Status).......No approved drug = high unmet need. 80,000 new cases per year in the U.S.

    AXS-02 Knee Osteoarthritis (OA) with Bone Marrow Lesions (BMLs) in Phase 3 (SPA & Fast Track).........7M patients in the U.S.

    AXS-02 Chronic Low Back Pain(CLBP) with Modic Changes (MCs) in Phase 3 ......1.6M patients in the U.S.

  • ah hah this puppy got massacred today after i got rid of holding 2 days ago ---> it's the biotech world people
  • APOLLO is listed as completing dosing in July and several weeks later presenting final results. I don’t recall ever seeing such a short turn-around. Such a rush could result in omissions and errors and the FDA might show a little backbone since being exposed on SRPT.
  • IONS out with piii results today -maybe not as good as expected -some serious side effects in some patients - perhaps its popping ALNY stock as it has competing drug ..
  • just cashed in my alny chips this afternoon at $74 merci $$$
    will return at the next big pull-back opportunity down the road
  • mther fckrs , every chance they have they say they have so much cash on hand and then they stab the invstors in the back
  • A positive earning of ALNY on May 9th. Slow and steady we are going up. See you at $66. Very lucky number!
  • Get into GWPH before it goes skyrocketing like alny. ALNY has squeezed over 20 points as the shorts scramble to cover their shorting. It will ease back after the bees left. Take profit now.
  • nice leap upward and a 52-week high today
  • what is the reason for the jump in price today?
  • The stock is on track for the $66 dollar target. Mark this post. You will see it before July.